The report covers market size by value and volume, CAGR forecasts, and emerging opportunities, the report delivers data-driven insights into industry developments, competitive trends, and future market outlook, enabling more effective strategic planning and market expansion
Efficacy At week 24, apitegromab treatment significantly reduced lean mass loss, preserving 1.9 kg (1.22.7, least square means (80% confidence interval (CI))) of lean mass compared to placebo (nominal, P = 0.0014)
No, there is no over the counter Ozempic
Notably, injection site discomfort with GHK-Cu tends to be more frequent than with other peptides, due to the copper component
You'll also have the opportunity to connect with our licensed Reframe coaches for more personalized guidance